Trademark Overview
On Thursday, March 12, 2026, a trademark application was filed for PROGRAM CANCER AGAINST ITSELF with the United States Patent and Trademark Office. The USPTO has given the PROGRAM CANCER AGAINST ITSELF trademark a serial number of 99699133. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, March 12, 2026. This trademark is owned by Earli Inc.. The PROGRAM CANCER AGAINST ITSELF trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:
Products for the prevention of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the localization of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for localization of cancer; Products for the therapy of cancer in humans, namely, pharmaceutical products to express a treatment agent for treating cancer; Products for the prevention of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the therapy of cancer in animals, namely, pharmaceutical products to express a treatment agent for treating cancer
Medical services for the prevention of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the localization of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for the localization of cancer; Medical services for the therapy of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for treating cancer; Medical services for the prevention of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in animals, namely, medical assay processing provided by medical labo...
